What type of study is this?

This is a Case Report study (also classified as: Pre-Registered Trial).

December 8, 2025Blood

Real-world efficacy and safety of mezigdomide-dexamethasone in heavily pre-treatred multiple myeloma patients: An Italian case series

View Full Paper

Ask AI

Bookmark

Authors

Observational analysis reveals 80% response rate in heavily pre-treated multiple myeloma, suggesting effective use of mezigdomide and dexamethasone.

Overall response rate was 80%, including complete and partial responses, and median follow-up of 7 months.
Progression-free survival and overall survival rates at 6 months were estimated at 58% and 69%, respectively.
Retrospective observational case series assessed patients treated with mezigdomide-dexamethasone in clinical practice across Italy.
Study indicates need for careful management of infectious complications to reduce treatment discontinuation.

Spadano et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

December 8, 2025Blood

View Full Paper

Ask AI

Bookmark

Authors

Observational analysis reveals 80% response rate in heavily pre-treated multiple myeloma, suggesting effective use of mezigdomide and dexamethasone.

Overall response rate was 80%, including complete and partial responses, and median follow-up of 7 months.
Progression-free survival and overall survival rates at 6 months were estimated at 58% and 69%, respectively.
Retrospective observational case series assessed patients treated with mezigdomide-dexamethasone in clinical practice across Italy.
Study indicates need for careful management of infectious complications to reduce treatment discontinuation.

Spadano et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark